Follow
Christian Klein
Christian Klein
Roche Pharma Research and Early Development, Roche Innovation Center Zurich
Verified email at roche.com
Title
Cited by
Cited by
Year
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski, Z Filipovic, N Kong, ...
Science 303 (5659), 844-848, 2004
54572004
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell …
E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ...
Blood, The Journal of the American Society of Hematology 115 (22), 4393-4402, 2010
10542010
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
8932018
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ...
Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011
5312011
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ...
The Journal of clinical investigation 122 (6), 1991-2005, 2012
5002012
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
R Stoll, C Renner, S Hansen, S Palme, C Klein, A Belling, W Zeslawski, ...
Biochemistry 40 (2), 336-344, 2001
3792001
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
3722015
p53 contains large unstructured regions in its native state
S Bell, C Klein, L Müller, S Hansen, J Buchner
Journal of molecular biology 322 (5), 917-927, 2002
3712002
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ...
Molecular cancer therapeutics 12 (10), 2031-2042, 2013
3702013
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ...
MAbs 5 (1), 22-33, 2013
3702013
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ...
Clinical Cancer Research 22 (13), 3286-3297, 2016
3422016
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
T Schlothauer, S Herter, CF Koller, S Grau-Richards, V Steinhart, C Spick, ...
Protein Engineering, Design and Selection 29 (10), 457-466, 2016
3062016
Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment
A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ...
Cancer cell 31 (3), 396-410, 2017
3012017
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization
Y Tomita, N Marchenko, S Erster, A Nemajerova, A Dehner, C Klein, ...
Journal of Biological Chemistry 281 (13), 8600-8606, 2006
3012006
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ...
Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011
3002011
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ...
Science translational medicine 12 (534), eaav7431, 2020
2932020
The N-terminal domain of p53 is natively unfolded
R Dawson, L Müller, A Dehner, C Klein, H Kessler, J Buchner
Journal of molecular biology 332 (5), 1131-1141, 2003
2782003
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ...
Blood, The Journal of the American Society of Hematology 122 (20), 3482-3491, 2013
2772013
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ...
MAbs 4 (6), 653-663, 2012
2662012
Targeting the p53–MDM2 interaction to treat cancer
C Klein, LT Vassilev
British journal of cancer 91 (8), 1415-1419, 2004
2632004
The system can't perform the operation now. Try again later.
Articles 1–20